Business Context and Reporting Period
This Form 8-K, filed on September 9, 2026, reports on events occurring on September 3, 2026, for BioLife Solutions, Inc. (BLFS). The filing addresses the status of the previously announced Agreement and Plan of Merger with Repligen Corporation, under which Repligen will acquire BioLife.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a current report focused on a corporate transaction event.
Transaction Consideration: Shareholders will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife common stock held.
Material Changes and Transaction Status
- HSR Waiting Period Expired: The required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired at 11:59 p.m. Eastern Time on September 3, 2026.
- Remaining Conditions: The completion of the Mergers remains subject to the adoption of the Merger Agreement by BioLife stockholders and other customary closing conditions.
- Stockholder Meeting: A special meeting to vote on the Merger Agreement is scheduled for October 5, 2026, at 9:00 a.m. Eastern Time, to be held via remote communication.
Outlook, Risks, and Contingencies
Management cautions that the transaction is subject to significant risks and uncertainties that could prevent completion or alter expected benefits. Key risks include:
- Failure to obtain necessary regulatory approvals or the imposition of adverse conditions.
- Failure to obtain BioLife stockholder approval at the special meeting.
- Termination of the Merger Agreement due to specific events or changes in circumstances.
- Integration challenges, potential dilution of Repligen shares, and diversion of management attention.
- Market risks regarding the cell therapy sector and competitive factors.
Investors are urged to read the Registration Statement on Form S-4 and the proxy statement/prospectus for detailed risk factors and additional information.
Investor Verification Checklist
- Verify the outcome of the BioLife stockholder special meeting scheduled for October 5, 2026.
- Confirm the final terms of the merger consideration ($11.25 cash + 0.1442 Repligen shares) in the definitive proxy statement.
- Monitor for any regulatory conditions imposed following the expiration of the HSR waiting period.
- Review the Form S-4 Registration Statement for detailed financial projections and synergy estimates.